Melanomas in younger patients are much more likely to be BRAF-positive than those in older patients (around 70% BRAF-positivity for patients <45 years has been reported but only 30% BRAF-positivity for those >70 years) but the response to BRAF inhibitors +/- a MEK inhibitor in patients >75 appears to be very similar to that in younger cohorts. Here, BRAF is linked to melanoma.